Cell Reports (Apr 2021)

The anti-inflammatory cytokine interleukin-37 is an inhibitor of trained immunity

  • Giulio Cavalli,
  • Isak W. Tengesdal,
  • Mark Gresnigt,
  • Travis Nemkov,
  • Rob J.W. Arts,
  • Jorge Domínguez-Andrés,
  • Raffaella Molteni,
  • Davide Stefanoni,
  • Eleonora Cantoni,
  • Laura Cassina,
  • Silvia Giugliano,
  • Kiki Schraa,
  • Taylor S. Mills,
  • Eric M. Pietras,
  • Elan Z. Eisenmensser,
  • Lorenzo Dagna,
  • Alessandra Boletta,
  • Angelo D’Alessandro,
  • Leo A.B. Joosten,
  • Mihai G. Netea,
  • Charles A. Dinarello

Journal volume & issue
Vol. 35, no. 1
p. 108955

Abstract

Read online

Summary: Trained immunity (TI) is a de facto innate immune memory program induced in monocytes/macrophages by exposure to pathogens or vaccines, which evolved as protection against infections. TI is characterized by immunometabolic changes and histone post-translational modifications, which enhance production of pro-inflammatory cytokines. As aberrant activation of TI is implicated in inflammatory diseases, tight regulation is critical; however, the mechanisms responsible for this modulation remain elusive. Interleukin-37 (IL-37) is an anti-inflammatory cytokine that curbs inflammation and modulates metabolic pathways. In this study, we show that administration of recombinant IL-37 abrogates the protective effects of TI in vivo, as revealed by reduced host pro-inflammatory responses and survival to disseminated candidiasis. Mechanistically, IL-37 reverses the immunometabolic changes and histone post-translational modifications characteristic of TI in monocytes, thus suppressing cytokine production in response to infection. IL-37 thereby emerges as an inhibitor of TI and as a potential therapeutic target in immune-mediated pathologies.

Keywords